Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II single-arm study of MAX-40279-01 plus azacitidine in adult myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia
CTR20211214Phase 2Active
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nefextinib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Guangzhou Zaiji Medical Technology. Started Sep 2021; status: active.
02
Drugs
nefextinib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20211214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211214.